Thymosin Alpha-1

Think of it as a foreign-licensed car that never passed the UK's MOT or registration. In many countries it is a road-legal, regulated vehicle with a real track record; in Britain you can only get a grey-import version with no paperwork, no safety check, and a sticker that says 'off-road use only'. The engineering behind it is genuine, more than most peptides can claim, but the version on the UK street isn't the regulated one the evidence was built on, and nobody has road-tested it for the journeys buyers actually want to make.

Tα1 is an N-terminal fragment of prothymosin alpha that acts as an immune modulator rather than a blanket stimulant. It signals through Toll-like receptors (especially TLR2 and TLR9) via the MyD88 pathway to promote maturation of dendritic cells, enhance MHC class I expression and NK-cell activity, and push T-cell differentiation toward a Th1 (anti-viral, anti-tumour) profile while reducing lymphocyte apoptosis. The net effect is restoration of dysregulated immune response toward balance. Administered by injection.

Research contexts. Not proven uses, and not recommendations.

Substantial and unusually real for a peptide of this type. Thymosin alpha-1 is an approved prescription medicine (thymalfasin/Zadaxin) in 35+ countries and has been evaluated in many human trials. Phase 3 chronic hepatitis B trials reported improved sustained virologic and serologic response versus control. In severe sepsis, the multicentre single-blind ETASS RCT (n=361) found lower 28-day all-cause mortality with treatment (26.0% vs 35.0%) but this primary endpoint did not reach statistical significance in the prespecified analysis (P=0.062); a secondary in-hospital mortality endpoint favoured treatment (28.7% vs 39.4%, P=0.032). Later meta-analyses of sepsis RCTs reported a pooled mortality benefit, though they pooled small, heterogeneous, mostly single-centre Chinese trials. COVID-19 data are largely observational. The evidence quality varies sharply by indication, and the popular non-medical uses (longevity, generic immune boosting) are not supported by this trial base.

• !Not licensed by the MHRA (UK) or FDA (US). UK supply is unlicensed 'research chemical' material sold 'not for human consumption', with no guarantee of identity, sterility or purity
• !Much of the favourable trial base comes from a concentrated set of (often Chinese) centres and includes single-blind designs; the landmark sepsis RCT (ETASS) actually missed significance on its primary 28-day mortality endpoint
• !As an immunomodulator it carries a theoretical risk of inappropriate immune activation; long-term safety outside studied indications is poorly characterised
• !Reported adverse effects in trials are generally mild (e.g. injection-site reactions), but real-world grey-market use bypasses the medical supervision and product quality the trial evidence relied on
• !Self-administering an injectable peptide for unproven indications (longevity, general 'immune boosting') is not supported by the licensed evidence base

Not a licensed medicine in the UK. Thymosin alpha-1 (thymalfasin) holds no MHRA marketing authorisation, despite being an approved prescription drug (Zadaxin) in 35+ other countries. It is not a controlled drug under the Misuse of Drugs Act, but as an injectable peptide it falls within the scope of the Human Medicines Regulations 2012. Selling or supplying it for human use without authorisation is unlawful, so in practice it is sold domestically only as a 'research chemical, not for human consumption'. There is no legitimate route to obtain it as a prescribed UK medicine, even for the indications it is approved for elsewhere.

• NCT04487444· Phase 2· Registered

  Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

  Registered trial of thymalfasin in COVID-19; illustrative of investigational interest. Human COVID-19 evidence overall remains limited/observational.

• · RCT (multicentre, single-blind)· Completed

  ETASS: Efficacy of Thymosin Alpha 1 for Severe Sepsis

  n=361 across six Chinese tertiary hospitals, 2008-2010. Primary endpoint (28-day all-cause mortality) did not reach statistical significance.

1. 01
   Thymosin alpha 1: A comprehensive review of the literature — Costantini E, et al., World Journal of Virology (2020)

   Narrative review covering mechanism, global approvals and the human trial base.

2. 02
   The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — Wu J, et al., Critical Care (2013)

   Landmark sepsis RCT, n=361. Primary endpoint (28-day all-cause mortality, 26.0% vs 35.0%) did NOT reach significance (P=0.062); secondary in-hospital mortality favoured treatment (28.7% vs 39.4%, P=0.032).

3. 03
   The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials — Liu F, et al., BMC Infectious Diseases (2016)

   Systematic review/meta-analysis suggesting a mortality benefit in sepsis (pooled RR ~0.59), drawn from small, mostly single-centre trials.

4. 04
   Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (regulatory status; thymosin alpha-1 not FDA-approved), U.S. Food and Drug Administration

   Illustrates that thymosin alpha-1 (thymalfasin) is not an FDA-approved medicine in the US; also not MHRA-approved in the UK.